Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary The President s FY 2009 Budget Request for the Centers for Disease Control and Prevention (CDC) discretionary funding is $5.9 billion (not including funding for the Agency for Toxic Substances and Disease Registry (ATSDR)), a decrease of $476 million, or 7.5 percent, below The CDC Budget Request is posted at: http://www.cdc.gov/fmo/pdfs/fy09_cdc_cj_final.pdf Highlights: $1.87 billion for Infectious Diseases, a decrease of $30 million, or 5.1 percent, below FY 2008. Highlights include: o $686 million for Immunizations/Respiratory Diseases, an increase of $1 million over Included in this is: $526 million for Immunizations, a decrease of $1 million below $465 million is mandatory funding and $61 million is for program operations. $160 million for Influenza, an increase of $3 million from In FY 2009, the funding request for Seasonal and Pandemic Influenza has been combined for a total budget request of $160 million. The request included $3 million for Seasonal Influenza, the same amount appropriated in FY 2008, and $157 million for Pandemic Influenza, an increase of $3 million over The program aims to minimize domestic and global illness, suffering, and death from seasonal influenza, investigate and contain the spread of avian influenza, and minimize the illness and death that will occur during the next influenza pandemic. The increase of $3 million will fund influenza pandemic preparedness priorities such as risk communications. o $1 billion for HIV/AIDS, Viral Hepatitis, STDs, and TB Prevention, a decrease of $2 million, or 0.2 percent below Included in this is: $691 million for HIV/AIDS, a $1 million decrease from $479 million for State and Local Health Departments, $24 million over FY 2008; $311 million for State and Local Prevention Projects, $4 million over FY 2008; $63 million for HIV/AIDS Testing, $11 million over FY 2008; $141 million for National, Regional, and Organizations programs, $24 million below FY 2008; and $71 million for CDC Research, Surveillance, and other activities, $1 million below Although overall funding for the HIV/AIDS, STDs, and TB account is decreased, HIV/AIDS testing is increased by $11 million for the Domestic Testing and Early Diagnosis Program. This is an initiative to increase testing in medical and communitybased settings, especially in areas and populations with the highest
burden of disease. There is also an increase in state and local health department funding, however this is mandatory funding via the Ryan White HIV/AIDS program; states must qualify for funding under this program. $18 million for Viral Hepatitis, the same as appropriated in $152 million for STDs, the same as appropriated in $140 million for TB, the same as appropriated in Funding for Tuberculosis (TB) will focus on a number of activities with state and local health departments. It will also work to decrease the importation of TB through the implementation of the Electronic Disease Notification (EDN) project, a web-based system that centralizes data sent to US quarantine stations, notifying them of newly arriving immigrants and refugees recently cured of TB or latently infected with M. tuberculosis. CDC is also building program and lab capacity for TB control programs in the Pacific Island jurisdictions by improving coordination at the regional reference lab, improving local capacity to conduct more specific tests, and improving procedures for specimen shipping. o $61 million for Zoonotic, Vector-Borne, and Enteric Diseases, a decrease of $7 million, or 10.3 percent, below $4 million for Hanta Virus/Special Pathogens, the same as appropriated in Funding for Hanta Virus/Special Pathogens will support basic and applied laboratory and epidemiologic research conducted at CDC and with partner organizations. Funding will be focused on developing rapid assays for detecting viruses or evidence of infection in humans and animal hosts. Funding will also support CDC s global response to special pathogens. $5 million for Lyme Disease, the same as appropriated in $26 million for West Nile Virus (WNV), a decrease of $7 million from The WNV program will continue to focus on disease surveillance and outbreak response, applied research to develop diagnostics, drugs, vaccines and surveillance and prevention tools, public health infrastructure and training, and disease prevention and control. According to budget documents, several years of CDC funding has allowed states to build an infrastructure, which has enabled them to better prevent, detect, and respond to the threat of WNV and other vector-borne infectious diseases. State public health officials have used federal dollars to leverage state funding. CDC will limit funding for extramural and intramural research in FY 2009. $28 million for Food Safety, the same as appropriated in FY 2009 funding for food safety will continue to support CDC s investigation, research, and response to foodborne and diarrheal diseases. It will also support enhanced collaborative surveillance
networks including FoodNet, PulseNet, OutbreakNet, and CaliciNet. $5 million for Chronic Fatigue Syndrome, the same as appropriated in o $123 million for Preparedness, Detection, and Control of Infectious Diseases, a decrease of $27 million, or 18 percent, below $16.502 million for Antimicrobial Resistance, a decrease of $417 thousand, or 2.5 percent below Antimicrobial resistance funds will support CDC s efforts to investigate, research, and respond to antimicrobial resistance diseases. Specifically, funds will be spent on improved monitoring of drug resistance and antimicrobial uses, improved prescription practices by health care providers and educating the public about health programs associated with inappropriate use of antimicrobial agents, and improved infection control practices in healthcare settings. Funding will also support the Pittsburgh Regional Health Initiative with hospitals in southern Pennsylvania to prevent health care associated infections via strong collaborative efforts to implement and evaluate a multifaceted strategy for prevention of MRSA in healthcare settings. Funds will also support the Active Bacterial Core Surveillance (ABCs) program. Pneumococcal data from ABCs will continue be used to determine which pneumococcal serotypes will be included in new vaccine formulations. Finally, funding will be used to develop appropriate antibiotic use measures for the National Committee for Quality Assurance s Healthcare Effectiveness Data and Information Set (HEDIS). $3 million for Patient Safety, the same as the FY 2008 appropriation. Patient Safety funds will be used to support laboratory training and proficiency testing programs with educational critiques for clinical microbiology laboratories in the U.S. and internationally to improve the accuracy of antimicrobial resistance detection and reporting, to improve patient care. Funding will also support CDC efforts to develop a plan for eliminating MRSA infections. Funds will also support implementation and evaluation of the Hospital Acquired Conditions provision in the Medicare 2007 Inpatient Prospective Payment System. Furthermore, funds will support the National Healthcare Safety Network (NHSN) activities. Rapid expansion of NHSN to meet state needs for mandated public reporting of healthcare-associated infections will continue in 2009 with the addition of all hospitals in 13 states. $104 million for all Other Infectious Diseases, a decrease of $26 million, or 20 percent below Funding for other infectious diseases will continue to support states with reagents and proficiency training materials to ensure
that lab tests are being properly performed. Funding will also support epidemiological studies and develop cutting edge lab tools for rapidly detecting new and reemerging infectious diseases. Additionally, CDC will work to develop a comprehensive electronic disease notification system to communicate with national and international partners regarding diseases and disease outbreaks occurring among mobile populations such as immigrants and refugees. Funding will also support CDC s work with partners to develop an enhanced communication and collaboration network among public health and clinical laboratories for emergency preparedness and public health surveillance. $137 million for Environmental Health, a decrease of $17 million or 11 percent below $302 million for Global Health, the same as the FY 2008 appropriation. o The Global Health program includes the Global AIDS program, the Global Immunization Program, Global Disease Detection, the Global Malaria Program and other Global Health Activities. Funding for the Global AIDS program provides technical assistance and support to PEPFAR country programs for the delivery of antiretroviral treatment (ART) to adults and children, the prevention, diagnosis and treatment of opportunistic infections including TB, and the prevention of mother-to-child transmission of HIV. The program also provides systematic training, guidance, and support for GAP staff, and PEPFAR partners on HIV diagnostics, ART resistance training, etc., and builds laboratory capacity. The FY 2009 request did not provide funds for CDC Buildings and Facilities. $55 million was provided in the FY 2008 appropriation. In FY 2009 request, CDC will sustain existing facilities with carryover balances from the previous appropriation. $1.419 billion for CDC Biodefense, a $60 million, or 4.1 percent, decrease from FY 2008. o $609 million for State and Local Capacity, a decrease of $137 million, or 18.4 percent below A decrease of funding in the Upgrading State and Local Capacity program is due to a one-time realignment of the grant cycle to allow the grant cycle to match the states fiscal year. o $101 million for the Biosurveillance Initiative, an increase of $48 million, or 90.6 percent above Of this increase, $16 million will enable BioSense to expand to over 800 users in 124 state and local public health jurisdictions by implementing new connections with emerging Regional Health Information Organizations (RHIOs) and Health Information Exchanges (HIEs), and $33 million will fund the operation of twenty quarantine stations throughout the U.S. and establish five new international stations. o $131 million for Upgrading CDC Capacity, an increase of $10 million, or 8.3 percent above This increase will be used to further develop CDC s
radiological response capabilities through the Laboratory Response Network (LRN). o $8 million for Anthrax Research, the same as the FY 2008 appropriation. o No funding was provided in the FY 2009 request or appropriated in FY 2008 for Botulinum Antitoxin Research. o $570 million for the Strategic National Stockpile, an increase of $19 million, or 3.3 percent above This increase will enable CDC to purchase, warehouse and manage medical countermeasures.